We have cloned and pharmacologically characterized the A 2B adenosine receptor (AR) from the dog, rabbit, and mouse. The full coding regions of the dog and mouse A 2B AR were obtained by reverse transcriptase-polymerase chain reaction, and the rabbit A 2B
1,3-di(n-propyl)xanthine ([ 3 H ]MRS 1754) bound with high affinity to membranes prepared from human embryonic kidney (HEK) 293 cells expressing mouse, rabbit, and dog A 2B ARs. Competition binding studies performed with a panel of agonist (adenosine and 2-amino-3,5-dicyano-4-phenylpyridine analogs) and antagonist ligands identified similar potency orders for the A 2B AR orthologs, although most xanthine antagonists displayed lower binding affinity for the dog A 2B AR compared with A 2B ARs from rabbit and mouse. No specific binding could be detected with membranes prepared from HEK 293 cells expressing the rabbit A 2B AR 103-111 variant. Furthermore, the variant failed to stimulate adenylyl cyclase or calcium mobilization. We conclude that significant differences in antagonist pharmacology of the A 2B AR exist between species and that some species express nonfunctional variants of the A 2B AR due to "leaky" splicing.
Four G protein-coupled receptors mediate the biological actions of adenosine designated A 1 , A 2A , A 2B , and A 3 adenosine receptors (AR) (Fredholm et al., 2001) . A 2B ARs have the unique property of coupling in cells to both G s and G q proteins, leading to a rise in intracellular cAMP and calcium levels (Auchampach et al., 1997; Feoktistov and Biaggioni, 1997; Gao et al., 1999; Fredholm et al., 2001) . Like the other three AR subtypes, the gene encoding the A 2B AR consists of two coding exons interrupted by a single intron, with splicing occurring at the region encoding the second intracellular loop in close proximity to the conserved aspartic acid-argininetyrosine (DRY) motif known to be important in regulating the conformational state and G protein coupling of G proteincoupled receptors (Fredholm et al., 2000; Rovati et al., 2007) . A 2B ARs are involved in control of vascular tone (Morrison et al., 2002) , cell growth (Dubey et al., 2000) , proinflammatory cytokine expression (Feoktistov et al., 2002; Zhong et al., 2004) , mast cell degranulation (Auchampach et al., 1997) , and epithelial water secretion (Strohmeier et al., 1995) . Currently, there is great interest in the development of selective A 2B AR antagonists that may be useful for treating a wide variety of diseases, including fibrotic lung disease, asthma, inflammatory bowel disease, and diabetes (Feoktistov and Biaggioni, 1997; Ji et al., 2001; Kim et al., 2002) . It is interesting that theophylline and enprofylline, drugs that have been used to treat asthma by mechanisms that remain undefined, inhibit A 2B ARs at therapeutically relevant concentrations (Auchampach et al., 1997; Kim et al., 2000 Kim et al., , 2002 Ji et al., 2001) .
To date the A 2B AR has been cloned from three different mammalian species: human, rat, and mouse. The structural homology of the A 2B AR among the three species is relatively high, sharing from 87 (human versus rat or mouse) to 95% (mouse versus rat) identity at the amino acid level. Despite a high degree of structural similarity, however, it has been suggested that the pharmacology of the A 2B AR may differ among species similar to that previously reported for A 1 and A 3 ARs. In a search for more selective antagonists for the human A 2B AR, Kim et al. (2000 Kim et al. ( , 2002 noticed that certain xanthine antagonists bound heterologously expressed recombinant rat A 2B ARs with up to 10-fold lower affinity compared with human A 2B ARs. Fozard et al. (2003) also suggested that antagonist pharmacology of A 2B ARs differs significantly among human, dog, rat, and guinea pig.
The purpose of the present investigation was to further explore the possibility that the pharmacological properties of A 2B ARs differ between species. Accordingly, we have compared the binding affinity of a panel of 10 different 1-, 3-, and 8-substituted xanthine derivatives as well as representative compounds from five additional classes of nonxanthine AR antagonists at recombinant mouse, rabbit, and dog A 2B ARs expressed in HEK 293 cells. We have also compared the binding affinity of seven different AR agonists composed of traditional adenosine analogs and substituted 6-amino-3,5-dicyano-4-phenylpyridine derivatives (Beukers et al., 2004; Eckle et al., 2007; Baraldi et al., 2008) . This work initially involved cloning the A 2B AR cDNA from the three different species. In the course of these studies, we identified an intriguing variant of the A 2B AR from the rabbit that we describe in detail that seems to result from "leaky" splicing.
Materials and Methods
Materials. All chemicals and ligands were purchased from Sigma-Aldrich (St. Louis, MO) and reconstituted in dimethyl sulfoxide unless stated otherwise. BAY 60-6583 was obtained from Dr. Thomas Krahn at Bayer Healthcare AG (Wuppertal, Germany), and BG 9719 was provided by Dr. Barry Ticho at Biogen IDEC (Cambridge, MA). Adenosine deaminase was from Roche (Indianapolis, IN), and pEGFP-N1 was from Clontech (Mountain View, CA). Cell culture media, such as Lipofectamine, Geneticin (G418 sulfate), fetal bovine serum, Thermoscript RT-PCR assay kits, Fura-2/AM and pcDNA3.1, were purchased from Invitrogen (Carlsbad, CA). Whatman GF/C glass fiber filters were from Brandel (Gaithersburg, MD). Bradford reagent was obtained from Bio-Rad (Hercules, CA). Primers for RT-PCR were from Operon Biotechnologies, Inc. (Huntsville, AL). Restriction endonuclease and cloning enzymes were purchased from New England Biolabs (Beverly, MA), Promega (Madison, WI), and Invitrogen. cAMP radioimmunoassay kits were purchased from Invitrogen and GE Healthcare (Chalfont St. Giles, UK), respectively.
A 2B AR cDNA Isolation. The full-length mouse and dog A 2B AR cDNAs were amplified by RT-PCR from brain (mouse) and large intestine (dog) total RNA using primers based on conserved regions within the 5Ј-and 3Ј-untranslated regions of the human, mouse, and rat A 2B ARs. A full-length rabbit A 2B AR cDNA clone was isolated from a brain cDNA library by plaque filter hybridization, as described previously (Auchampach et al., 1997) , using a fragment of the dog A 2B AR as a probe.
Creation of Stable HEK 293 Cell Lines Expressing A 2B ARs. Full-length A 2B AR cDNAs were subcloned into the mammalian expression vector pcDNA3.1. The plasmids were transfected into HEK 293 cells using Lipofectamine and selected with G418 (2 mg/ml). Cell lines derived from individual clones were maintained in cell culture media (Dulbecco's modified Eagle's medium with 10% fetal bovine serum and antibiotics) containing 0.6 mg/ml G418. The full-length rabbit A 2B AR and the rabbit A 2B AR 103-111 variant were also subcloned into pEGFP-N1 between the KpnI and NheI sites to allow for expression of the A 2B AR variants fused at the C-terminal end with enhanced green fluorescent protein (GFP). Stable HEK 293 cell lines expressing these constructs were used to examine the expression and subcellular localization of the two receptor variants by laser scanning confocal microscopy (Nikon C1 confocal laser-scanning microscope system).
Analysis of A 2B AR 103-111 mRNA Expression. RT-PCR was used to detect mRNA expression of the A 2B AR 103-111 variant in rabbit and mouse tissues. One microgram of total RNA was reverse-transcribed using poly-T primers. The resulting cDNA was amplified by PCR (up to 40 cycles) with primers spanning the splicing region and electrophoresed through 3% agarose gels. The primers for amplification in rabbit studies were forward primer ϭ 5Ј-CTT CCA CAG CTG CCT CTT TC-3Ј and reverse primer ϭ 5Ј-ACC CAG AGG ACA GCA ATG AC-3Ј. Primers for amplification in mouse studies were forward primer ϭ 5Ј-TGC TCA CAC AGA GCT CCA TC-3Ј and reverse primer ϭ 5Ј-AGT CAA TCC AAT GCC AAA GG-3Ј.
Synthesis of 6-Amino-3,5-dicyano-4-phenylpyridine AR Agonists. We synthesized a series of 6-amino-3,5-dicyano-4-phenylpyridine derivatives (compounds 1-3) to test in binding assays according to the scheme shown in Fig. 1 . Compound 4 (BAY 60-6583) was obtained from Bayer.
Radioligand Binding Assays. Radioligand binding assays were conducted with crude membrane fractions. HEK 293 cells expressing A 2B ARs were washed in phosphate-buffered saline followed by homogenization in cold (4°C) HEPES buffer (10 mM Na ϩ -HEPES, 10 mM EDTA, and 0.1 mM benzamidine, pH 7.4) using a glass Dounce homogenizer and centrifuged at 20,000g for 30 min. Cell pellets were washed twice with HE buffer (10 mM Na ϩ -HEPES, 1 mM EDTA, and 0.1 mM benzamidine, pH 7.4). After the washes, pellets were resuspended in HE buffer with 10% (w/v) sucrose. Samples were aliquoted and stored at Ϫ20°C until further use in binding assays after the protein concentration was determined by the Bradford assay.
For equilibrium binding assays, crude membranes were incubated with radioligands and competitors in 100 l of HE buffer in siliconized glass tubes containing 5 mM MgCl 2 and 5 U/ml adenosine deaminase unless indicated otherwise. Nonspecific binding was determined in most assays by including 100 M adenosine-5Ј-N-ethylcarboxamide (NECA). After incubating at 21°C for 3 h, the bound and free radioligands were separated by filtration over glass fiber filters presoaked in 0.5% polyethylene amine to reduce nonspecific binding.
For saturation experiments with [ 3 H]MRS 1754, specific binding data fit optimally to a single-site binding model using Marquardt's nonlinear least-squares interpolation, from which K d and B max values were obtained. For competition studies, IC 50 values were fit to eq. 1:
where i is the number of binding sites, SB is specific binding, and NS is nonspecific binding. cAMP Accumulation Assays. HEK 293 cells were detached from cell culture plates, resuspended in serum-free DMEM containing 25 mM HEPES, pH 7.4, 1 U/ml adenosine deaminase, and 20 M Ro 20,1724 (phosphodiesterase inhibitor), and then transferred to polypropylene tubes (50,000 cells/tube). The cells were incubated with ligands for 15 min at 37°C with shaking, after which the assays were terminated by adding 500 l of 0.15 N HCl. cAMP in the acid extract was determined by radioimmunoassay.
Intracellular Ca 2؉ Assays. HEK 293 cells were detached from cell culture plates and loaded with 1 M Fura-2/AM in buffer containing 100 mM NaCl 2 , 5 mM KCl, 1 mM MgSO 4 , 1 mM KH 2 PO 4 , 25 mM NaHCO 3 , 0.5 mM CaCl 2 , 2.7 g/liter D-glucose, 20 mM Na-HEPES, pH 7.4, and 0.25% bovine serum albumin for 45 min. Cells
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were washed and resuspended in the same buffer (1 ϫ 10 6 /ml) without bovine serum albumin plus the addition of 1 U/ml adenosine deaminase. Fluorescence at baseline and after the addition of agonists was continuously measured with a spectrofluorimenter (BD Biosciences, Franklin Lakes, NJ) in a stirred thermostable cuvette (30°C) using an emission wavelength of 510 nm and excitation wavelengths of 340 and 380 nm.
Results
Molecular Cloning of Mouse, Rabbit, and Dog A 2B ARs. We chose to characterize mouse, rabbit, and dog A 2B ARs, given that these species are commonly used in experimental animal models of disease. We obtained the mouse A 2B AR cDNA for expression studies by RT-PCR because the sequence for this receptor has already been reported previously (GenBank accession number NM_007413). We were also able to amplify the full-length dog A 2B AR cDNA using primers (forward 5Ј-GGC CAT GCA/T GCT A/GGA GAC-3Ј; reverse 5Ј-AGG CC/GA GAG CCT AGA/G TCA-3Ј) corresponding to untranslated 5Ј and 3Ј ends that were highly conserved between sequences for the rat (GenBank accession number NM_017161), human (GenBank accession number AY136748), and mouse. However, all efforts to obtain the rabbit A 2B AR cDNA sequence by RT-PCR failed, requiring use of a traditional library screening approach. We screened a total of 1 ϫ 10 6 plaque-forming units from a rabbit brain cDNA library using a fragment of the dog A 2B AR as a probe. One positively hybridizing clone containing a 1.5-kilobase insert was sequenced in full (103 and 785 bp of 5Ј-and 3Ј-untranslated sequence and 332 bp of coding sequence) and was determined to correspond to the rabbit A 2B AR based on sequence homology and pharmacological characteristics. Sequences for the rabbit and dog were submitted to GenBank (accession numbers AY630339 and AY313204, respectively). Alignment of the amino acid sequences of the A 2B ARs from the mouse, rabbit, and dog, with sequences previously reported for the human and rat, is shown in Fig. 2 . All five cloned receptors encode a protein consisting of 332 amino acids. Between species, the greatest degree of homology lies within the transmembrane regions, whereas the least degree of homology lies within the second extracellular loop and the distal half of the carboxyl tail. Unlike the A 2A AR (which also couples to G s proteins) but similar to A 1 and A 3 ARs, sequence of the carboxyl tail of the cloned A 2B AB from the various species is relatively short (ϳ40 amino acids versus ϳ70 -80 amino acids for A 2A ARs) and contains a conserved putative palmitoylation site at cysteine 311 of the consensus sequence. Of the five mammalian species of A 2B AR cloned to date, the rat and mouse A 2B ARs display the greatest (95% identical) degree of sequence similarity, whereas the rat and the human sequences vary the most (87%; Fig. 2) . Overall, Fig. 1 . Synthetic routes to 6-amino-3,5-dicyano-4-phenylpyridine derivatives. Benzaldehyde or 4-hydroxybenzaldehyde was reacted with cyanothioacetamide and a catalytic amount of triethylamine (Et 3 -N) in ethanol to generate compounds 1 and 2. Compound 2 was further reacted with 2-chloroacetamide and sodium hydrogen carbonate in dimethyl formamide (DMF) to generate compound 3. The compounds were decolorized with activated carbon and recrystallized from methanol or ethanol. Identity of the compounds was performed by melting point analysis, infrared spectroscopy, and NMR. Compound 4 (BAY 60-6583) was provided by Bayer Healthcare. sequence variability of the A 2B AR among the same five species is similar to that of A 1 and A 2A ARs (92-98 and 81-95% similarity, respectively) but less compared with the A 3 AR, whereby sequence similarity ranges from 69 (rat versus rabbit) to 88% (mouse versus rat).
During the course of cloning the rabbit A 2B AR cDNA by library screening, we identified an additional A 2B AR clone (1.3 kilobases) encoding a 323 amino acid protein. The predicted amino acid sequence of this clone, designated A 2B AR [103] [104] [105] [106] [107] [108] [109] [110] [111] , is identical to that of the full-length rabbit A 2B AR clone described above, with the exception that amino acids 103 to 111 are absent (Fig. 3) . This nine amino acid deletion is located at the only known splice junction within the coding region of the A 2B AR in the second intracellular loop, which led us to speculate that this clone encodes a splice variant. Indeed, analysis of the A 2B AR sequence suggests that the A 2B AR 103-111 variant results from the use of an alternative 5Ј donor site (see Fig. 3 ) that is also found in the dog A 2B AR sequence but not in the mouse, rat, or human sequences. Splicing normally occurs within the highly conserved DRY motif implicated in conferring constitutive activity, G protein coupling, and receptor stabilization in other G protein-coupled receptors (Fredholm et al., 2000; Rovati et al., 2007) . It is interesting that this motif is conserved in the A 2B AR 103-111 variant (Fig. 3) . Trace mRNA expression of the variant was identified in rabbit brain by RT-PCR (Fig. 4) , but no detectable expression was consistently identified in other tissues where the A 2B AR is abundantly expressed, including the spleen, small intestine, and large intestine (data not shown). Expression of a similar variant of the A 2B AR was not identified in mouse tissues, including the brain (Fig. 4) .
We subsequently generated a stable HEK 293 cell line expressing the A 2B AR 103-111 clone to determine whether this variant is capable of activating similar signal transduction pathways as the full-length A 2B AR, i.e., G s protein-mediated activation of adenylyl cyclase by cAMP accumulation assays and G q protein-mediated Ca 2ϩ mobilization using Fura-2 fluorescence. Comparisons were made with stable HEK 293 cell lines transfected with the full-length rabbit A 2B AR clone or the empty pcDNA3.1 vector. We used HEK 293 cells for these assays because they endogenously express the A 2B AR coupled to adenylyl cyclase and Ca 2ϩ mobilization at low levels (Cooper et al., 1997; Gao et al., 1999) , ensuring that we would be using a cell system capable of supporting A 2B AR signaling. As shown in Fig. 5 , the potency and efficacy of the nonselective AR agonist NECA to increase intracellular concentrations of cAMP and Ca 2ϩ were increased significantly in HEK 293 cells transfected with the full-length rabbit A 2B AR compared with cells transfected with the empty vector. However, responses to NECA using cells transfected with the A 2B AR 103-111 clone were essentially identical to those observed in vector control cells. Similar results were obtained in experiments using Chinese hamster ovary cells or COS-7 cells to express the receptors (data not shown). These findings indicate that the A 2B AR 103-111 variant does not couple to the same signaling pathways as the full-length A 2B receptor. Because responses elicited by A 2B ARs endogenously expressed in HEK 293 cells were not altered, these results also indicate that the variant does not have dominant-negative activity.
We also conducted radioligand binding assays to determine whether we could detect binding to the A 2B AR 103-111 variant in crude membrane fractions obtained from transfected HEK 293 cells. As shown in Fig. 6 , we did not detect specific binding with [ 3 H]MRS 1754 or [ 3 H]1-,3-dipropyl-8-cyclopentylxanthine (CPX) in assays using membranes prepared from A 2B AR 103-111 cells based on inclusion of 100 M NECA, 5 M CPX, 2 mM enprofylline, or 10 M xanthine amine congener (XAC) to define nonspecific binding, whereas substantial specific binding was detected with both radioligands using membranes from HEK 293 cells transfected with the full-length A 2B AR clone. Similar negative results were obtained in binding assays using higher concentrations of the radioligands (up to 50 nM) as well as [
3 H]ZM 241385 and 125 I-ZM 241385 (data not shown).
Because we were not able to detect functional coupling or radioligand binding, stable cell lines expressing A 2B AR- brain was reverse-transcribed, subjected to 40 cycles of PCR amplification using species-specific primers spanning the splicing region, and subjected to gel electrophoresis, as described under Materials and Methods. The lane labeled Control contained reactions that included fulllength (mouse) or a mixture of full-length and A 2B AR 103-111 variant cDNAs (rabbit), and the lane labeled H 2 O contained reactions using water in place of cDNA. For studies using rabbit cDNA, a 171-bp fragment corresponds to the full-length receptor, and a 144-bp fragment corresponds to the splice variant. Only a single 158-bp fragment was detected in studies using mouse cDNA, which corresponds to the fulllength mouse A 2B AR receptor. GFP fusion proteins were generated to confirm that the A 2B AR 103-111 variant is expressed in HEK 293 cells and to compare its subcellular localization to the full-length A 2B AR using confocal microscopy. We confirmed that the A 2B AR 103-111 variant is indeed expressed in HEK 293 cells (Fig. 7) . Unlike the full-length A 2B AR, however, distinct expression of the A 2B AR 103-111 variant at the plasma membrane was not evident. We next conducted competition binding assays to compare the binding profiles of a series of xanthine and nonxanthine antagonists. The xanthine compounds included the 1-, 3-, and/or 8-substituted xanthines, including enprofylline, theophylline, 8-PT, 8-SPT, 1,3-dipropyl-8-p-sulfophenylxanthine (DP-SPX), XAC, CPX, and BG 9719. The nonxanthine compounds included the adenine antagonist N-0861, the triazolotriazine derivative ZM 241385, the pyridine derivative MRS 1523, and (Shryock et al., 1992; Poucher et al., 1995) . MRS 1523 is a relatively potent and moderately selective human/rodent A 3 AR antagonist (Li et al., 1998) . K i values of these compounds for the dog, rabbit, and mouse A 2B AR are shown in Table 1 , and, if available, previously reported K i values for the human and rat A 2B ARs are also included. For all species, a close correlation between relative affinities of xanthine and nonxanthine antagonists for the A 2B AR was found with no striking differences in potency orders (Table 1 and Fig. 9 ). However, affinities for the xanthine compounds were generally lower for the dog and rat A 2B AR versus the other species by as much as 7-fold (Table 1 and Fig. 9 ). The largest differences occurred with compounds that bound with high affinity, including MRS 1754 (7.2-fold comparing dog versus rabbit) and XAC (6.7-fold comparing dog versus rabbit).
Finally, we conducted competition assays with [ 3 H]MRS 1754 to compare the binding profile of adenosine and nonadenosine agonist ligands. All agonist competition binding data fit best to a one-site model and were not shifted in assays containing 100 M guanosine 5Ј-O-(␥-thio)triphosphate (Fig. 10) or in assays where Mg 2ϩ was not included in the binding buffer (data not shown). Thus, values obtained in agonist competition binding assays reflect binding to the low affinity, G protein-uncoupled state of the receptor. Table 2 reports K i values for agonist ligand binding to mouse, rabbit, and dog A 2B ARs. The adenosine analogs included the nonselective agonist NECA, the A 1 AR-selective agonist (Ϫ)-N 6 -(2-phenylisopropyl)adenosine (R-PIA), and the potent A 3 AR agonist IB-MECA. The 6-amino-3,5-dicyano-4-phenylpyridine analogs included compounds 1 to 3 depicted in Fig. 1 and the newly discovered selective A 2B AR agonist, BAY 60-6583. Unlike antagonists, no differences in agonist binding affinities were identified among the three species (Table 2 and Fig. 8 ). In terms of adenosine analogs, NECA bound with highest affinity to the A 2B AR from all three species, with K i values averaging between 1 and 3 M, whereas IB-MECA and R-PIA bound with ϳ10 to 20-fold lower affinity. The 2-carbamylmethylthio-substituted 4-phenylpyridine analogs (compounds 3 and 4) bound with relatively high affinity to A 2B ARs displaying affinities ranging between 100 and 750 nM among the three different species.
Discussion
We have cloned and characterized by competition radioligand binding analysis agonist and antagonist pharmacology of the A 2B AR from the mouse, rabbit, and dog. Our results demonstrate that the primary structure of the A 2B AR is highly conserved among mammalian species, and that this translates into similar binding characteristics of synthetic AR ligands. We noticed only slight differences in antagonist pharmacology of the A 2B AR from the various species. In particular, we observed that the canine A 2B AR tended to bind xanthine antagonists with lower affinity than rabbit and mouse A 2B ARs. Our findings are similar to those of Kim et al. (2002) , who also detected small species differences in antagonist binding to A 2B ARs. These investigators noticed in competition binding assays using recombinant receptors that rat A 2B ARs tended to bind certain xanthine antagonists with lower affinity compared with human A 2B ARs by up to 10-fold. Similar to our work, the differences were more prominent with potent antagonists such as MRS 1754. Combining the results of this previous study by Kim et al. (2002) with our data, we propose that human, rabbit, and mouse A 2B ARs have similar binding characteristics, whereas dog and rat A 2B ARs can be categorized as having lower binding potency for xanthine antagonists. Our results also agree with those of Fozard et al. (2003) , who suggested that antagonist pharmacology of the dog A 2B AR differs from that of A 2B ARs from human, rat, and guinea pig based on pK b values calculated from bioassays of various smooth muscle preparations. In contrast, we observed no species differences in agonist binding to A 2B ARs. Our analysis included adenosine analogs as well as members of a new class of substituted 6-amino-3,5-dicyano-4-phenylpyridine agonist ligands recently reported to potently activate the human A 2B AR (Beukers et al., 2004; Eckle et al., 2007; Baraldi et al., 2008) . It is notable that agonist binding to the A 2B AR in our assays was GTPinsensitive ( Fig. 10) . Thus, agonist affinity values provided in this report reflect binding to the low affinity, G proteinuncoupled form of the A 2B AR. It is presumed that expression of specific G protein subunits required for high-affinity agonist binding is low in HEK 293 cells, such that heterologous overexpression of the A 2B AR predominantly results in a large pool of uncoupled receptors. It has been reported that other G s protein-coupled receptors, including the A 2A AR, also couple poorly when expressed in HEK 293 cells (Murphree et al., 2002) .
Both A 1 and A 3 ARs exhibit species differences in ligand binding that are much more pronounced than those observed in the present investigation with A 2B ARs. In regard to the A 1 AR, affinities of certain N 6 -substituted adenine ligands (i.e., agonists such as R-PIA and antagonists including N-0861) and 8-substituted xanthine antagonists, including 8-PT and CPX vary as much as 200-fold among the different species that have been examined extensively (Murphy and Snyder, 1982; Ukena et al., 1986; Tucker et al., 1994) . In regard to the A 3 AR, xanthine and nonxanthine antagonists are well known to bind rodent A 3 ARs, with nearly 500-fold lower potency than A 3 ARs from nonrodent species, including human (Linden, 1994; Auchampach et al., 1997; Li et al., 1998) . Until recently, MRS 1523 has been the only readily available antagonist with a binding potency for rodent A 3 ARs that is lower than 1 M (Li et al., 1998; Kreckler et al., 2006 ). Significant differences in agonist ligand binding also exist between human and rodent A 3 ARs (Melman et al., 2008) . The complex pharmacology of the A 3 AR has hindered progress toward understanding the biological role of this AR subtype and explains why it remained undiscovered until it was cloned in 1991 (Meyerhof et al., 1991; Zhou et al., 1992) . Unlike the A 3 AR, the pharmacology of A 1 ARs differs among species, even though its structure is highly conserved (Ͼ90% identical at the amino acid level).
Substantial species differences in pharmacology have been observed for many other families of G protein-coupled receptors, including ␣-adrenergic, serotonin, and histamine receptors. In many cases, single amino acid mutations were found jpet.aspetjournals.org to be responsible for these differences, usually in transmembrane regions V to VII that predominantly form the ligand binding pocket (Cherezov et al., 2007; Jaakola et al., 2008) . In-depth analysis of species differences in pharmacology coupled more recently with molecular modeling and direct structural information has been proven to be a useful strategy in identifying crucial amino acids for ligand-receptor interactions. Upon analysis of the A 2B AR sequences (Fig. 2) , no remarkable amino acid substitutions were found within any of the transmembrane regions. Substantial sequence variability was found, however, in the second extracellular loop region between transmembrane segments IV and V, and most notably, the canine A 2B AR uniquely lacked the variable amino acid at position 152. A recent crystallographic model of the A 2A AR bound to the antagonist ligand ZM 241385 suggests that antagonist ligands interact with both the second and third extracellular loops of this receptor in addition to multiple transmembrane regions (Jaakola et al., 2008) . Therefore, we speculate that differences in the second extracellular loop region could explain the lower binding affinity observed for the canine homolog of the A 2B AR. Through the analysis of interspecies chimeric receptors, Stra␤er et al. (2008) have determined that the second extracellular loop contributes to interspecies differences in pharmacology of the histamine H 1 receptor. Our antagonist binding data reported in Table 1 highlight very useful information. Note that CPX and ZM 241385, compounds that are commonly used in biological studies as selective A 1 and A 2A AR antagonists, respectively, display relatively high-binding affinity for A 2B ARs from the various species. Thus, these compounds are not particularly useful for discriminating A 1 or A 2A versus A 2B AR-mediated responses. Two other compounds that are preferable for selectively inhibiting A 1 ARs include the 8-bicyclo xanthine antagonist BG 9719 and, in particular, the adenine antagonist N-0861; both are potent A 1 AR antagonists (K i ϳ1 nM) (Shryock et al., 1992; Pfister et al., 1997) that are 700 to 1000-fold and Ͼ15,000-fold selective versus A 2B ARs, respectively. The results of our binding data also confirm that MRS 1523 displays low binding potency for A 2B ARs, ensuring that this compound is unlikely to nonspecifically inhibit A 2B ARs, even at high concentrations required to inhibit A 3 ARs.
Our receptor binding assays were conducted with the relatively new radioligand [ 3 H]MRS 1754 (Ji et al., 2001 ). This ligand displays higher affinity compared with other radiolabels that have been used previously to characterize A 2B ARs, including [ 3 H]ZM 241385 (Ji and Jacobson, 1999) , [ 125 I]3-(4-amino-3-iodobenzyl)-8-(phenyl-4-oxyacetate)-1-propyl xanthine (Kim et al., 2000) , and [ 3 H]CPX (Robeva et al., 1996) , which bind to A 2B ARs with K d values ranging from 30 to 60 nM. Although [ 3 H]MRS 1754 is highly lipophilic resulting in considerable nonspecific binding, this problem can be minimized by presoaking filters with 0.5% polyethyleneimine (Ji et al., 2001 ). We also found that binding assays were improved by using siliconized glass tubes and by adding membrane proteins to binding assays before adding [ 3 H]MRS 1754 to prevent nonspecific binding to the assay tubes. In general, we found that nonspecific binding comprised 50% of total binding included in assays at concentrations equivalent to the K d . Note that while MRS 1754 was identified as a potent and moderately selective human A 2B AR antagonist (400-, 245-, and 123-fold selective versus A 1 , A 2A , and A 3 ARs), it is not selective versus the A 1 AR in the rat, in part due to its lower binding affinity for rat A 2B ARs (Kim et al., 2000 (Kim et al., , 2002 . Considering the results of the present investigation, it is possible that MRS 1754 also possesses limited selectivity for A 2B ARs from other species as well.
During the process of cloning the rabbit A 2B AR, we isolated a clone shown to be expressed in rabbit brain at very low levels that encodes an A 2B AR variant lacking 9 amino acids in the second intracellular loop, which we have designated A 2B AR [103] [104] [105] [106] [107] [108] [109] [110] [111] . This variant probably resulted from leaky splicing due to the presence of an additional 5Ј donor site in the rabbit sequence (Fig. 2) . Although the A 2B AR 103-111 variant seems to encode a G protein-coupled receptor protein that remains in-frame and retains the highly conserved DRY motif, it did not bind antagonist AR ligands or couple to G protein signaling pathways when expressed in HEK 293 cells. Shortening the second intracellular loop presumably constrains proper orientation of the ␣-helical transmembrane regions of the receptor, thereby disrupting the ligand binding pocket (Cherezov et al., 2007; Jaakola et al., 2008) . Although we cannot exclude the possibility that this variant couples to other unique signaling pathways, serves nonsignaling functions (i.e., participates in receptor dimerization or facilitates trafficking of other receptors) (Milligan and Smith, 2007) , or binds other ligands (i.e., netrin-1) (Corset et al., 2000) , this variant seems to be a nonfunctional form of the A 2B AR found in rabbits and possibly other species. A similar splice variant with questionable physiological significance containing a 17 amino acid insertion within the second intracellular loop of the A 3 AR has also been identified previously in the rat (Sajjadi et al., 1996) .
In summary, we have systematically compared agonist and antagonist pharmacology of A 2B ARs from three species commonly used in preclinical animal models of human disease. Our results suggest that small but significant differences in antagonist ligand binding exist between species. Our cloning results also demonstrate that some species may express variants of the A 2B AR due to alternative or leaky splicing. The results of this work should aid with further elucidation of the pathophysiological roles of the A 2B AR.
